Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Imatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 20/20 | 0.99 |
| ▸ | BCR known ✓ | P11274 | 14/20 | 0.99 |
| ▸ | KIT known ✓ | P10721 | 12/20 | 0.99 |
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 0.93 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.99 |
| ▸ | RAD52 | P43351 | 1/20 | 0.99 |
| ▸ | ABL2 | P42684 | 7/20 | 0.93 |
| ▸ | LYN | P07948 | 3/20 | 0.93 |
| ▸ | SRC | P12931 | 2/20 | 0.93 |
| ▸ | SYK | P43405 | 2/20 | 0.93 |
| ▸ | PLK4 | O00444 | 1/20 | 0.93 |
| ▸ | DDX3X | O00571 | 1/20 | 0.93 |
| ▸ | GAK | O14976 | 1/20 | 0.93 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.93 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.93 |
| ▸ | CA12 | O43570 | 1/20 | 0.93 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.93 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.93 |
| ▸ | EGFR | P00533 | 1/20 | 0.93 |
| ▸ | CA1 | P00915 | 1/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Imatinib SCHEMBL1060852 | 0.99 | ABL1 (1.00) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL1673189 | 0.99 | ABL1 (1.00) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL29370699 | 0.99 | ABL1 (1.00) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL726190 | 0.99 | ABL1 (1.00) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL29377238 | 0.99 | ABL1 (1.00) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL8217 | 0.99 | ABL1 (1.00) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL15632914 | 0.99 | ABL1 (1.00) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL1439360 | 0.99 | ABL1 (0.99) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL5004429 | 0.98 | ABL1 (0.97) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL15201213 | 0.97 | ABL1 (0.98) | ABL1BCRKITPDGFRARAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107625773-A | The pharmaceutical composition and its preparation of a kind of imatinib mesylate | 海南锦瑞制药有限公司 | 2018-01-26 | — | — | CN | claimed |
| CN-104027336-A | Medicament composition of imatinib mesylate and preparation of medicament composition | HAINAN JINRUI PHARMACEUTICAL | 2014-09-10 | — | — | CN | claimed |
| CN-103989683-A | Pharmaceutical composition of imatinib mesylate and preparation thereof | HAINAN JINRUI PHARMACEUTICAL | 2014-08-20 | — | — | CN | claimed |
| US-7300938-B2 | Polymorphs of imatinib mesylate | HETERO DRUGS LIMITED (IN) | 2007-11-27 | — | — | US | claimed |
| US-20050234069-A1 | Novel polymorphs of imatinib mesylate | HETERO DRUGS LIMITED (IN) | 2005-10-20 | — | — | US | claimed |
| WO-2004106326-A1 | NOVEL POLYMORPHS OF IMATINIB MESYLATE | HETERO DRUGS LIMITED (IN) | 2004-12-09 | — | — | WO | claimed |
| CN-107625773-A | The pharmaceutical composition and its preparation of a kind of imatinib mesylate | 海南锦瑞制药有限公司 | 2018-01-26 | — | — | CN | disclosed |
| CN-107625773-A | The pharmaceutical composition and its preparation of a kind of imatinib mesylate | 海南锦瑞制药有限公司 | 2018-01-26 | — | — | CN | disclosed |
| US-9439903-B2 | Process for the preparation of amorphous imatinib mesylate | CADILA HEALTHCARE LIMITED (IN) | 2016-09-13 | — | — | US | disclosed |
| CN-104027336-A | Medicament composition of imatinib mesylate and preparation of medicament composition | HAINAN JINRUI PHARMACEUTICAL | 2014-09-10 | — | — | CN | disclosed |
| CN-104027336-A | Medicament composition of imatinib mesylate and preparation of medicament composition | HAINAN JINRUI PHARMACEUTICAL | 2014-09-10 | — | — | CN | disclosed |
| CN-103989683-A | Pharmaceutical composition of imatinib mesylate and preparation thereof | HAINAN JINRUI PHARMACEUTICAL | 2014-08-20 | — | — | CN | disclosed |
| CN-103989683-A | Pharmaceutical composition of imatinib mesylate and preparation thereof | HAINAN JINRUI PHARMACEUTICAL | 2014-08-20 | — | — | CN | disclosed |
| US-20080234286-A1 | STABLE AMORPHOUS IMATINIB MESYLATE AND PRODUCTION PROCESS THEREFOR | CHEMAGIS LTD. (IL) | 2008-09-25 | — | — | US | disclosed |
| WO-2008112722-A2 | IMATINIB MESYLATE | DR. REDDY'S LABORATORIES LTD. (IN) | 2008-09-18 | — | — | WO | disclosed |
| US-7300938-B2 | Polymorphs of imatinib mesylate | HETERO DRUGS LIMITED (IN) | 2007-11-27 | — | — | US | disclosed |
| EP-1857454-A1 | Crystalline imatinib base and production process therefor | CHEMAGIS LTD. (IL) | 2007-11-21 | — | — | EP | disclosed |
| US-20060223817-A1 | Crystalline imatinib base and production process therefor | CHEMAGIS LTD. (IL) | 2006-10-05 | — | — | US | disclosed |
| US-20050234069-A1 | Novel polymorphs of imatinib mesylate | HETERO DRUGS LIMITED (IN) | 2005-10-20 | — | — | US | disclosed |
| WO-2004106326-A1 | NOVEL POLYMORPHS OF IMATINIB MESYLATE | HETERO DRUGS LIMITED (IN) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223817-A1 | Crystalline imatinib base and production process therefor | ABL1, ABL2, ROS1 | ABL1 1/4885BCR 33/4885KIT 65/4885 |
| US-20080234286-A1 | STABLE AMORPHOUS IMATINIB MESYLATE AND PRODUCTION PROCESS THEREFOR | ABL1, ABL2, WASF2 | ABL1 1/4885BCR 68/4885KIT 10/4885 |
| US-20050234069-A1 | Novel polymorphs of imatinib mesylate | ABL1, ABL2, PDGFRA | ABL1 1/4885BCR 55/4885KIT 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.